CD274 and neoplasm: Anti-PD-L1 or GB1211 administration as monotherapies resulted in a non-significant reduction in tumor growth.Following combination treatment ofGB1211 and anti-PD-L1 antibody final tumor volume and weight (31.3% and 40.1% reduction, respectively) were significantly reduced compared with vehicle control (Figures 3A, B, respectively).